ATE123221T1 - Kristalline 7-(2-(2-aminothiazol-4-yl)-2- hydroxyiminoacetamido)-3-vinyl-3-cephem-4- carboxyl-säure (syn isomer). - Google Patents

Kristalline 7-(2-(2-aminothiazol-4-yl)-2- hydroxyiminoacetamido)-3-vinyl-3-cephem-4- carboxyl-säure (syn isomer).

Info

Publication number
ATE123221T1
ATE123221T1 AT88113311T AT88113311T ATE123221T1 AT E123221 T1 ATE123221 T1 AT E123221T1 AT 88113311 T AT88113311 T AT 88113311T AT 88113311 T AT88113311 T AT 88113311T AT E123221 T1 ATE123221 T1 AT E123221T1
Authority
AT
Austria
Prior art keywords
hydroxyiminoacetamido
cephem
vinyl
crystalline
syn isomer
Prior art date
Application number
AT88113311T
Other languages
English (en)
Inventor
Takao Takaya
Fumiyuki Shirai
Hitoshi Nakamura
Yasunobu Inaba
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16519432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE123221(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of ATE123221T1 publication Critical patent/ATE123221T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/22—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with radicals containing only hydrogen and carbon atoms, attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT88113311T 1987-08-19 1988-08-17 Kristalline 7-(2-(2-aminothiazol-4-yl)-2- hydroxyiminoacetamido)-3-vinyl-3-cephem-4- carboxyl-säure (syn isomer). ATE123221T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20619987 1987-08-19

Publications (1)

Publication Number Publication Date
ATE123221T1 true ATE123221T1 (de) 1995-06-15

Family

ID=16519432

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88113311T ATE123221T1 (de) 1987-08-19 1988-08-17 Kristalline 7-(2-(2-aminothiazol-4-yl)-2- hydroxyiminoacetamido)-3-vinyl-3-cephem-4- carboxyl-säure (syn isomer).

Country Status (11)

Country Link
US (1) US4935507A (de)
EP (1) EP0304019B1 (de)
KR (1) KR970008126B1 (de)
AT (1) ATE123221T1 (de)
AU (1) AU617347B2 (de)
CA (1) CA1297096C (de)
DE (1) DE3853901T2 (de)
ES (1) ES2072856T3 (de)
HK (1) HK18496A (de)
IE (1) IE67348B1 (de)
ZA (1) ZA885709B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405283B (de) 1997-04-04 1999-06-25 Biochemie Gmbh Neues kristallines 7-(z)-(2-(2-aminothiazol-4-yl) -2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4- carbonsäure dicyclohexylammoniumsalz und verfahren zu dessen herstellung
US6888124B1 (en) 1999-03-24 2005-05-03 Shell Oil Company Method to monitor internal parameters of electrical motor systems
US20050020561A1 (en) * 2001-04-17 2005-01-27 Yatendra Kumar Process for the preparation of cefpodoxime acid
KR100451672B1 (ko) * 2001-06-05 2004-10-08 한미약품 주식회사 결정성 세프디니르 산부가염, 이의 제조방법 및 이를이용한 세프디니르의 제조방법
KR20030018536A (ko) * 2001-08-30 2003-03-06 임득수 유리제품의 표면처리방법
WO2003050124A1 (en) * 2001-12-13 2003-06-19 Ranbaxy Laboratories Limited Crystalline cefdinir potassium dihydrate
US7297800B2 (en) * 2001-12-27 2007-11-20 Ajinomoto Co., Inc. Process of producing glutamate derivatives
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
ITMI20020913A0 (it) * 2002-04-29 2002-04-29 Acs Dobfar Spa Nuova forma cristallina del cefdinir
US6800756B2 (en) * 2002-05-03 2004-10-05 Orchid Chemicals And Pharmaceuticals, Ltd. Method for the preparation of ceftiofur sodium and its intermediates
WO2004016623A1 (en) * 2002-08-13 2004-02-26 Sandoz Ag A cefdinir intermediate
CA2484871C (en) 2002-08-26 2010-11-30 Ajinomoto Co., Inc. Novel aldolase and production process of substituted .alpha.-keto acids
US7244842B2 (en) * 2002-11-15 2007-07-17 Orchid Chemicals & Pharmaceuticals Ltd. Amorphous hydrate of a cephalosporin antibiotic
EP2557160A3 (de) 2002-12-09 2013-03-27 Ajinomoto Co., Inc. Mutierte D-Aminotransferase und Verfahren zur Herstellung optisch aktiver Glutaminsäurederivate damit
ITMI20022724A1 (it) * 2002-12-20 2004-06-21 Antibioticos Spa Sali cristallini del cefdinir.
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
US20070106073A1 (en) * 2003-03-24 2007-05-10 Eiji Imai Novel crystal of 7-[2-[(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) and method for preparation thereof
WO2004104010A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Crystalline form of cefdinir
US20040242556A1 (en) * 2003-06-02 2004-12-02 Ramesh Dandala Novel crystalline form of cefdinir
US20050137182A1 (en) * 2003-06-02 2005-06-23 Ramesh Dandala Novel crystalline form of cefdinir
WO2004111059A1 (en) * 2003-06-19 2004-12-23 Orchid Chemicals & Pharmaceuticals Ltd A process for the preparation of a cephalosporin antibiotic
US20050059818A1 (en) * 2003-09-12 2005-03-17 Duerst Richard W. Polymorph of a pharmaceutical
US20050059819A1 (en) * 2003-09-12 2005-03-17 Duerst Richard W. Cefdinir pyridine salt
US20050113355A1 (en) * 2003-09-12 2005-05-26 Duerst Richard W. Cefdinir pyridine salt
US20080139528A1 (en) * 2003-12-10 2008-06-12 Pujara Chetan P Cefdinir oral suspension
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
US20060142563A1 (en) * 2004-03-16 2006-06-29 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060211676A1 (en) * 2004-03-16 2006-09-21 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20060142261A1 (en) * 2004-03-16 2006-06-29 Devalina Law Crystalline anhydrous cefdinir and crystalline cefdinir hydrates
US20050209211A1 (en) * 2004-03-16 2005-09-22 Devalina Law Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
US20060069079A1 (en) * 2004-09-27 2006-03-30 Sever Nancy E Stable amorphous cefdinir
US20050245738A1 (en) * 2004-05-03 2005-11-03 Lupin Ltd Stable bioavailable crystalline form or cefdinir and a process for the preparation thereof
WO2006018807A1 (en) * 2004-08-16 2006-02-23 Ranbaxy Laboratories Limited Crystalline forms of cefdinir
WO2006059753A1 (en) * 2004-11-30 2006-06-08 Astellas Pharma Inc. Novel oral pharmaceutical suspension of cefdinir crystal
GB2421024A (en) * 2004-12-07 2006-06-14 Sandoz Ag Cefdinir crystalline form C
WO2006117794A1 (en) * 2005-05-02 2006-11-09 Hetero Drugs Limited A novel crystalline form of cefdinir
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
JP2008526782A (ja) * 2005-10-31 2008-07-24 テバ ファーマシューティカル インダストリーズ リミティド セフジニルセシウム塩結晶
KR20080064990A (ko) * 2005-10-31 2008-07-10 테바 파마슈티컬 인더스트리즈 리미티드 세프디니르의 제조방법
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
ITMI20071628A1 (it) 2007-08-06 2007-11-05 Acs Dobfar Spa Sintesi di 3-alchenilcefalosporine e nuovi intermedi utili ad esse correlati
CN101481383B (zh) * 2008-12-31 2012-01-11 杭州奥默医药技术有限公司 头孢地尼酸式复盐化合物及制备方法
TR201000686A1 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
EP2862569A1 (de) 2011-09-09 2015-04-22 Cubist Pharmaceuticals, Inc. Verfahren zur Behandlung von intrapulmonalen Infektionen
CN102643293A (zh) * 2012-03-30 2012-08-22 石药集团中诺药业（石家庄）有限公司 头孢地尼三元复合物及其用于制备头孢地尼的方法
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
CN103012433B (zh) * 2012-12-13 2015-06-24 珠海保税区丽珠合成制药有限公司 头孢地尼晶型b的制备方法
EP2893929A1 (de) 2013-03-15 2015-07-15 Cubist Pharmaceuticals, Inc. Antibiotische Ceftolozanzusammensetzungen
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140275000A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
WO2015035376A2 (en) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
CN103622933B (zh) * 2013-12-19 2015-04-08 石家庄市华新药业有限责任公司 一种头孢地尼胶囊及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8323034D0 (en) * 1983-08-26 1983-09-28 Fujisawo Pharmaceutical Co Ltd 7-substituted-3-vinyl-3-cephem compounds

Also Published As

Publication number Publication date
DE3853901T2 (de) 1995-10-12
IE67348B1 (en) 1996-03-20
ES2072856T3 (es) 1995-08-01
EP0304019A2 (de) 1989-02-22
EP0304019B1 (de) 1995-05-31
KR970008126B1 (ko) 1997-05-21
AU617347B2 (en) 1991-11-28
KR890003778A (ko) 1989-04-18
CA1297096C (en) 1992-03-10
US4935507A (en) 1990-06-19
DE3853901D1 (de) 1995-07-06
EP0304019A3 (en) 1990-12-27
AU2099888A (en) 1989-02-23
ZA885709B (en) 1989-04-26
IE882411L (en) 1989-02-19
HK18496A (en) 1996-02-09

Similar Documents

Publication Publication Date Title
ATE123221T1 (de) Kristalline 7-(2-(2-aminothiazol-4-yl)-2- hydroxyiminoacetamido)-3-vinyl-3-cephem-4- carboxyl-säure (syn isomer).
DK0513543T3 (da) Amidinophenylalaninderivater, fremgangsmåde til deres fremstilling, deres anvendelse og antikoagulationsmidler med indehold deraf
NO882036D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske ketoner.
HU9600452D0 (en) Compounds avaiable for preparation of isoxazole-derivatives
NO160076C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzoksazol- og benzotianolaminderivater.
ATE269290T1 (de) Benzoylderivate
ES523344A0 (es) Un procedimiento de preparacion de derivados de bencimidazol (divisional de la patente de invencion num. 514.947, presentada el 12 de agosto 1982)
ES2031865T3 (es) Un procedimiento para preparar derivados de imidas.
IT1229528B (it) Sali cefalosporinici e relative composizioni iniettabili, nonche' procedimento di preparazione
FI861562A (fi) Substituerade n-/(4-piperidinyl) alkyl/-bicykliska kondenserade oxazol- och tiazolaminer.
HUT43939A (en) Herbicide comprising substituted semicarbazone or thiosemicarbazone derivatives as active substance and process for preparing the active substance
NO166283C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 7beta-(2-(5-amino-1,2,4-tiadiazol-3-yl)-2(z)-substituertoksyiminoacetamido)-3-(heterocyclylmetyl)-3-cefem-4-karboksylsyrederivater.
IL57392A (en) 7-(2-(2-aminothiazolyl)-(2-methoxyimino))acetamido-3-(di-and tetrahydrotriazinyl)thiomethyl-3-cephem-4-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
NO167737C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydroimidazo(1,4)benzodiazepin-2-oner.
NO171313C (no) Fremgangsmaate for fremstilling av krystaller av 7beta-((z)-2-(5-amino-1,2,4-tiadiazol-3-yl)-2-metoksyiminoacetamido)-3-(1-imidazo(1,2-b)-pyridazinium)metyl-3-cefem-4-karboksylathydroklorid
EP0050286A3 (en) Novel pharmaceutical guanidine derivatives
DK0402806T3 (da) Krystallinske cephem-syreadditionssalte og fremgangsmåde til fremstilling heraf
NO171502C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive thiadiazolylacetamidcefem-derivater
FI894125A0 (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisen 3-piperidinyyli-indatsolin valmistamiseksi
ES2097002T3 (es) Procedimiento para convertir loracarbef dihidrato en loracarbef monohidrato.
DE69007777D1 (de) Derivate der p-Guanidinobenzoesäure zur Behandlung der zerebrovaskulären Kontraktion.
PT73948B (en) Process for the preparation of biologically active heterobicyclic hydroximidates and thiolhydroximidates and carbamate ester derivatives thereof